API Manufacturing

The Importance of Process Understanding

Headquartered in Ann Arbor, Michigan, Cayman Chemical Company has been supplying scientists worldwide with the resources necessary for advancing human and animal health since 1980. In 2004, Cayman Chemical began supporting the pharmaceutical industry with their first API, Latanoprost. Cayman Pharma (formerly NeraPharm) was acquired by Cayman Chemical in 2006, bringing substantial commercial experience with prostaglandin synthesis together with extensive dedicated GMP-certified production space and highly trained staff. Both companies have unparalleled experience and expertise in prostaglandin chemistry, custom route development of unique molecules, and the manufacture of GMP-compliant APIs used in both human and veterinary medicine.

- Employees worldwide: 480
- Manufacturing capacity: 30-40 kg annually (scale-up possible)
- Certified and registered EMA and US FDA facilities
- Cayman Pharma – ISO 9001, ISO 14001, OHSAS 18001 certifications
- APIs developed using non-infringing routes of synthesis (statements available upon request)
- API and impurities reference standards available
- DEA licensed facility for manufacturing, analysis, and export

Commercial API production

We currently manufacture the following APIs according to the latest ICH and CGMP requirements for commercial distribution. Contact our sales department for more information about pricing and availability.

- **CGMP Bimatoprost**
- **CGMP Latanoprost (CEP granted)**
- **CGMP Latanoprostene Bunod**
- **CGMP Tafluprost**
- **CGMP Travoprost**
- **CGMP Epoprostenol sodium salt**
- **CGMP (+)-Cloprostenol sodium salt**
- **CGMP (±)-Cloprostenol sodium salt**

Development API production

- **Psilocin**
- **Psilocybin**

Cayman Pharma s.r.o.

Phone: (+420) 313 033 155
GMP-API@caymanpharma.com